Semaglutide is not recommended for individuals with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, individuals with a history of pancreatitis, or those who have had a prior serious hypersensitivity reaction to Semaglutide or any of its components.
In March 2024, Wegovy was also approved to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular (heart, blood vessel) disease and either obesity or overweight
The finding, the researchers say, suggests there are multiple ways the drug benefits the heart, rather than its protective effect on cardiovascular health being due solely to weight loss
As with Ozempic, any potential side effects, including hair-related concerns, should be discussed with a healthcare provider
Last year, the Federal Trade Commission (FTC) challenged what it called "junk patent listings" by several pharmaceutical companies, including Novo Nordisk for its patent listing for Ozempic, Saxenda, and Victoza
.jpg)
